Begin typing your search above and press return to search.

Donald Trump administration secures almost entire world stock of Remdesivir

The Donald Trump administration has secured nearly the entire world stock of antiviral drug remdesivir from US-based Gilead

Donald Trump

Sentinel Digital DeskBy : Sentinel Digital Desk

  |  2 July 2020 8:52 AM GMT

NEW YORK: The Donald Trump administration has secured nearly the entire world stock of antiviral drug remdesivir from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key COVID-19 drug for the rest of the world.

As a result of an agreement with the drug maker announced earlier this week, the US Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September.

This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials, the US Health and Human Services said.

The agreement allows hospitals in the US to purchase the drug in amounts allocated by HHS and State Health departments.

Hospitals in the US will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course.

"President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for COVID-19," US Health and Human Services Secretary Alex Azar said in a statement.

"To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people."

Remdesivir is considered a key drug in the fight against COVID-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. To expand supply of remdesivir, Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan The agreements allow the companies — Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. — to manufacture remdesivir for distribution in 127 countries. (IANS)

Also Watch: CPI(M) Protests against Fuel Price Hike in Naharkatia

Next Story